Cancer Molecular Genetics Prgm

癌症分子遗传学（CMG）计划是一个新成立的计划，由于重组 将前癌症细胞生物学计划分为两个更小，更有凝聚力的计划[另一个是 癌症细胞信号传导（CCS）程序]。该计划的成员在遗传学和 表观遗传变化是导致癌症发展的分子和细胞事件的基础， 进展CMG计划的主要科学目标是确定导致癌症的基因 发展和进展，以确定调节表达的遗传和表观遗传机制， 这些基因在正常细胞和癌细胞中，以确定它们在控制细胞的性质和行为中的作用。 癌细胞，以确定机制，通过该机制，可以利用癌细胞中已确定的缺陷来选择性地 诱导癌细胞死亡，并最终利用这些知识开发创新方法， 治疗目前难治的癌症。 CMG计划由来自八个学术部门的22名调查人员组成的多学科小组组成 医学和牙科学院的学生CMG计划的资金基础超过540万美元 每年直接资助300万美元，其中超过420万美元来自NIH或其他同行评审资金 源CMG计划的成员有多个完善和富有成效的合作， 在该计划内，并与其他弗吉尼亚联邦大学（VCU）梅西癌症的成员 中心（MCC）的计划，这导致了联合资助的研究计划和高影响力 近年来出版。CMG计划的189篇出版物中超过四分之三 在过去的赠款期间，成员的捐款来自与其他管理协委会成员的合作。其中52% 涉及项目内，48%涉及项目间合作，21%涉及项目内和项目间合作。 跨计划合作。 CMG计划的中心目标是促进实现MCC的总体目标，即 将实验室的进步带入临床，以改善癌症的诊断和治疗。通过获得更好的 了解癌症发展和进展的潜在分子基础，将有可能 开发下一代癌症治疗方法。

The Cancer Molecular Genetics (CMG) program is a newly formed program resulting from the restructuring of the former Cancer Cell Biology program into two smaller and more cohesive programs [the other being the Cancer Cell Signaling (CCS) program]. Members of this program share a common interest in the genetic and epigenetic changes that underlie the molecular and cellular events contributing to cancer development and progression. The primary scientific goals of the CMG program are to define the genes contributing to cancer development and progression, to identify the genetic and epigenetic mechanisms regulating expression of these genes in normal and cancer cells, to determine their role in governing the properties and behaviors of cancer cells, to identify mechanisms by which identified defects in cancer cells can be exploited to selectively induce cancer cell death, and ultimately to use this knowledge to develop innovative approaches for the treatment of currently intractable cancers. The CMG program consists of a multidisciplinary group of 22 investigators from eight academic departments from the Schools of Medicine and Dentistry. The CMG program has a funding base of over $5.4 million dollars in annual direct support, of which more than $4.2 million is from NIH or other peer-reviewed funding sources. Members of the CMG program have multiple well-established and productive collaborations, both within the program and with members of other Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) programs, which have resulted in jointly funded research initiatives and high-impact publications in recent years. Greater than three-quarters of the 189 publications from CMG program members in the past grant period resulted from collaborations with other MCC members. 52% of which involved intra-programmatic, 48% involved inter-programmatic collaborations, and 2 1% involved both intra and inter- programmatic collaborations. The central goal of the CMG program is to facilitate achievement of the overarching goal of the MCC, namely to move laboratory advances into the clinic for improved diagnosis and therapy of cancer. By gaining a better understanding of the underlying molecular basis of cancer development and progression, it will be possible to develop the next generation of cancer therapeutics.